For semaglutide specifically, the semaglutide reconstitution process and tirzepatide reconstitution process each have specific water-to-peptide ratios that affect both dosing accuracy and solution stability
CEO Lee stated, D&D Pharmatech continues platform-based clinical expansion across two pillars: liver disease and CNS. He added, Histological results and additional biomarker data for DD01 will be released in the second quarter of this year. During the Q&A session after the presentation, a question was raised about DD01's strategic positioning, given that recently approved GLP-1 agonists for obesity treatment, such as Wegovy and Mounjaro, are now expanding into MASH indications
doi: 10.1089/gtmb.2011.0347 97 ZhangQBaiBMeiXWanCCaoHDanLet al
It eliminates the need for ongoing medication management and the associated risks of adverse drug interactions
Public-private partnerships and ongoing innovation in telehealth technology can open new doors for patients, making care more efficient, effective, and accessible
New developments should target some of the problems associated with existing treatments, such as muscle mass lost on GLP1s, she suggests